US20130288280A1 - Alzheimer's diagnosis - Google Patents
Alzheimer's diagnosis Download PDFInfo
- Publication number
- US20130288280A1 US20130288280A1 US13/929,600 US201313929600A US2013288280A1 US 20130288280 A1 US20130288280 A1 US 20130288280A1 US 201313929600 A US201313929600 A US 201313929600A US 2013288280 A1 US2013288280 A1 US 2013288280A1
- Authority
- US
- United States
- Prior art keywords
- vlp
- levels
- disease
- kit
- tau
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
Definitions
- the invention relates to a method and kits to diagnose neurodegenerative disease such as Alzheimer's disease. More specifically, it concerns the methods used to diagnose disease using biomarkers.
- AD Alzheimer's disease
- post-mortem examination of brain tissue is the only tool for definitive diagnosis. Therefore, the development of a biomarker for AD would aid greatly in the diagnosis of this disease. In addition, such a marker could potentially be utilized to measure efficacy in future therapeutic trials.
- AD Alzheimer's disease
- amyloid plaques are extracellular proteinaceous aggregates. They are principally composed of the amyloid- ⁇ peptide (A ⁇ ), a 38-42 amino acid peptide fragment of the amyloid precursor protein (APP).
- a ⁇ amyloid- ⁇ peptide
- APP amyloid precursor protein
- Neurofibrillary tangles are intraneuronal protein aggregates found mainly in neuritis. The neurofibrillary tangles are primarily composed of hyperphosphorylated Tau (pTau), a microtubule-associated protein.
- biomarkers that may have utility in the diagnosis of AD, are biomarkers that reflect neuronal death rather than specific markers of disease pathogenesis. Such markers may provide information about disease progression related to functional outcome, and have utility in future clinical trials testing therapeutic efficacy.
- VLP-1 Visinin-like protein 1
- a calcium sensor protein which is expressed in high abundance in neurons of the central nervous system.
- VLP-1 is elevated in the CSF of rats following transient focal ischemia, and is detectable in elevated concentrations in the plasma of ischemic stroke patients.
- the use of VLP-1 as a marker for brain damage and for AD has been described in PCT publication WO 2006/012351.
- VLP-1 indicates brain damage, it has also been identified as a useful diagnostic for Alzheimer's disease.
- Alternative causes for brain damage are associated with readily identified conditions such as stroke, asphyxiation, invasive surgery and trauma.
- the invention provides methods that include the VLP-1 biomarker to predict the imminence and progression of Alzheimer's disease.
- an elevated level of VLP-1 is detected in bodily fluids, e.g., in cerebrospinal fluid or in serum, it is associated with brain injury such as that caused by Alzheimer's disease (AD).
- AD Alzheimer's disease
- the invention is directed to a method to diagnose AD which method comprises evaluating VLP-1 in combination with at least one other biomarker selected from amyloid- ⁇ peptide (A ⁇ ), hyperphosphorylated Tau (pTau) and total Tau (tTau). Evaluating VLP-1 in combination with another biomarker gives rise to an improved diagnostic method better than that of relying on the interpretation of any one biomarker alone. Evaluating VLP-1 in combination with copy presence of a ApoE ⁇ 4 allele also improves the diagnostic method.
- a ⁇ amyloid- ⁇ peptide
- pTau hyperphosphorylated Tau
- tTau total Tau
- kits for diagnosis which contain reagents for quantifying the biomarker targets including VLP-1 and at least one of A ⁇ , pTau, tTau present in the biological fluid samples, as well as kits that contain reagents for quantifying VLP-1 and assessing the presence or absence of the ApoE2 4 allele.
- FIG. 1 shows CSF VLP-1 levels in AD patients and controls.
- the line within the box represents the median value; the box encompasses 25th-75th percentiles; and the error bars encompass the 10th-90th percentiles.
- a significant difference was found in control vs. AD patients; p ⁇ 0.001, Student's T-test.
- FIGS. 2A and 2B show the predictive ability of AD biomarkers to diagnose AD vs. Control.
- FIG. 2A shows the area under ROC curve (AuC) and its 95% confidence interval for VLP-1, A ⁇ , pTau and an optimum linear combination of all 3 biomarkers (ALL).
- FIG. 2B shows CSF levels of VLP-1, A ⁇ , and pTau plotted on a 3-D graph (controls, solid circles; AD, open circles).
- FIG. 3 shows VLP-1 levels by ApoE genotype.
- Mean CSF VLP-1 levels are graphed according to ApoE genotypes ( ⁇ 3/ ⁇ 3, ⁇ 3/ ⁇ 4,).
- Mean VLP-1 levels in ApoE ⁇ 4/ ⁇ 4 were more than twice that in ⁇ 3/ ⁇ 3 individuals; *p ⁇ 0.0 (3/3 vs. 4/4); **p ⁇ 0.0 (3/4 vs. 4/4); using ANOVA with post-hoc Tukey's test.
- FIGS. 4A-4C show correlation of VLP-1 and pTau levels in CSF.
- FIG. 4A shows CSF VLP-1 levels plotted against A ⁇ .
- FIG. 4B shows CSF VLP-1 levels plotted against tTau.
- VLP-1 levels in biological fluids correlate with the incidence of brain damage associated with Alzheimer's disease. It has now been found that by combining the results of determining VLP-1 levels with at least one alternative marker, selected from amyloid ⁇ peptide, hyperphosphorylated Tau, and total Tau, the accuracy of diagnosis can be improved. The accuracy can also be improved by correlation of VLP-1 levels with an ApoE ⁇ 4 genotype.
- the levels in a patient to be diagnosed are determined and compared with levels in normal controls.
- a standard value for normals with appropriate error bars can be generated by averaging the results from a statistically meaningful sample of individuals known not to be afflicted by this condition.
- levels of VLP-1, tTau and pTau are significantly higher in AD patients and levels of A ⁇ 1-42 are lower.
- the average values for controls with appropriate error bars are shown in Table 2.
- the levels of the relevant markers in normal controls may be determined experimentally in the course of performing the method of the invention with respect to a test subject on a statistically meaningful number of subjects, typically 10 or more subjects, 20 or more subjects, 30 or more subjects or 50 or more subjects.
- values associated with levels of these markers in normal controls may also be published in the literature; in such instances it is unnecessary to determine the levels of a published marker in normal controls, but rather these values can be obtained by consulting the literature. The practitioner will understand when, and whether, published values for the level of a particular marker is sufficiently reliable, and has been determined by methods sufficiently similar to that used in performing the test on test subjects to be satisfactory for making the comparison.
- kits designed for conducting the method of the invention will contain reagents for the determination of VLP-1 plus the reagents for determination of at least one additional marker or for determining the presence of an ApoE 4 allele.
- the nature of the reagents will depend on the type of methodology used in performing the test. If immunological assays such as radioimmunoassays, ELISA's, or Western blot are to be employed, antibodies reactive with the marker, such as VLP-1, will be included. Such antibodies may be polyclonal or monoclonal or recombinantly produced. As the assays are performed in vitro, humanized forms are unnecessary, but are not excluded from use in the practice of the invention. Generally, these are less preferred in this context, however, as the affinity tends to be lower.
- kits will contain instructions for conducting the determinations of marker levels, and may further contain directions for statistical comparisons between levels in test subjects and those in normal controls.
- test subjects are typically those persons identified as at risk for Alzheimer's disease but may also include individuals who are lacking in any symptoms that would lead to a suspicion of susceptibility.
- the subjects may have already been shown to have elevated levels of one of the markers employed in the method of the invention, in which case the result of the previous test in combination with the test for at least one additional marker constitute the data provided for conduct of the method of the invention.
- the invention further includes a method of simply assessing the results of previous determinations of one or more markers in combination with an level of VLP-1 and need not include physically determining the levels of these previously measured markers.
- the methods of the invention also include simply comparing the levels of VLP-1 and at least one additional marker selected from amyloid- ⁇ peptide, hyperphosphorylated Tau, and total Tau that have previously been determined in a test subject with levels previously determined in control subjects and determining whether the levels of both markers are different in the test subject in the predicted way in order to determine the presence of absence of Alzheimer's disease in the test subject.
- Biological fluids that are possible sample sources include blood and fractions thereof, such as plasma or serum, cerebrospinal fluid, urine, and lymphatic fluids. Serum or plasma or urine are more convenient. Cerebrospinal fluid is the preferred source for sampling.
- NINCDS-ADRDA criteria for probable AD Thirty-three (33) patients with a clinical diagnosis of AD (NINCDS-ADRDA criteria for probable AD) were evaluated. Twenty-four (24) healthy controls also participated and were free of neurological or psychiatric disorders. All subjects underwent a clinical evaluation which included a medical history, physical and neuropsychiatric evaluation, and a Mini-Mental State Examination (MMSE). ApoE genotype was also assessed. See Table 1.
- the mean age of subjects in each group did not differ significantly (controls: 68.5 years vs. AD 64.9 years). Gender distribution was also not significantly different (46% vs. 55%). The mean duration of disease in the AD group was 3.9 years. MMSE scores were assessed and were significantly lower in the AD group (23.0 vs. 29.8, p ⁇ 0.001).
- CSF samples were collected by lumbar puncture at the L3/L4 interspace. The first portion of the sample was discarded, and the subsequent 10 mls was collected in polypropylene tubes, centrifuged at 2,000 g for 10 min (to eliminate cells), and frozen in aliquots at ⁇ 80° C. All samples had less than 500 erythrocytes/ ⁇ l.
- CSF samples were assayed for total Tau (tTau) and hyperphosphorylated Tau (pTau at Thr-181), and A ⁇ 1-42 using sandwich ELISA's, as previously described (Blennow, K., et al., Mol. Chem. Neuropathol. ( 1995) 26:231-245; Vanmechelen, E., et al., Neurosci. Lett. ( 2000) 285:49-52).
- CSF VLP-1 was measured using a sandwich ELISA (monoclonal antibody for capture and rabbit polyclonal antibody for detection), as described (Laterza, O. F., et al., Clin. Chem. (2006) 52:1713-1721).
- a ⁇ 1-42 levels were lower in AD patients compared to controls (p ⁇ 0.001, Table 2), consistent with numerous other studies (Arai, et al., supra; Blennow, et al., supra; Tapiola, et al., supra; Andreasen, et al., supra).
- the units in Table 2 are pg/mL of CSF.
- VLP-1 levels in the CSF were significantly higher in the AD patients compared to controls (387 ⁇ 27 vs. 234 ⁇ 21, p ⁇ 0.001, FIG. 1 ).
- FIG. 2A The area under the ROC curves for VLP-1, A ⁇ , pTau, and an optimum linear combination of all biomarkers is shown in FIG. 2A .
- the linear combination resulted in an approximately 5% improvement in diagnostic accuracy.
- FIG. 2B The 3-D plot ( FIG. 2B ) demonstrates that higher levels of VLP-1 and pTau, and lower levels of A ⁇ 1-42 result in AD diagnosis.
- the ApoE ⁇ 4 genotype may be associated with increased neuronal death.
- VLP-1 and tTau, pTau, or A ⁇ 1-42 were performed; VLP-1 and shown in FIGS. 4A-4C .
Abstract
Evaluation of VLP-1 levels in combination with at least one of amyloid-β peptide (Aβ), hyperphosphorylated tau (pTau) or total tau (tTau) levels in samples of biological fluid improves the accuracy of diagnosis of Alzheimer's disease.
Description
- This application is a divisional of U.S. patent application Ser. No. 12/674,153 which is the U.S. national phase of PCT application PCT/US2008/073851 having an international filing date of 21 Aug. 2008, which claims priority to U.S. Provisional Application Ser. No. 60/957,132 filed 21 Aug. 2007. The contents of these documents are incorporated herein by reference.
- The invention relates to a method and kits to diagnose neurodegenerative disease such as Alzheimer's disease. More specifically, it concerns the methods used to diagnose disease using biomarkers.
- The diagnosis of Alzheimer's disease (AD), the most common form of dementia in Western countries, is largely based on historical and clinical criteria. Although many studies report a reasonably high degree of diagnostic accuracy (80-90%), often these studies include patients evaluated at specialized centers with advanced disease. At present, post-mortem examination of brain tissue is the only tool for definitive diagnosis. Therefore, the development of a biomarker for AD would aid greatly in the diagnosis of this disease. In addition, such a marker could potentially be utilized to measure efficacy in future therapeutic trials.
- Most studies of AD biomarkers to date have focused on known pathological substrates for the disease. Pathological hallmarks of AD include amyloid plaques and neurofibrillary tangles, both comprised primarily of abnormally aggregated endogenous proteins. Amyloid plaques are extracellular proteinaceous aggregates. They are principally composed of the amyloid-β peptide (Aβ), a 38-42 amino acid peptide fragment of the amyloid precursor protein (APP). The major species, a 42-amino acid peptide (Aβ1-42), is significantly decreased in the cerebrospinal fluid (CSF) of patients with AD. Neurofibrillary tangles are intraneuronal protein aggregates found mainly in neuritis. The neurofibrillary tangles are primarily composed of hyperphosphorylated Tau (pTau), a microtubule-associated protein. Several studies have shown that total Tau (tTau) and pTau are elevated in AD CSF.
- Although studies exploring the use of these two biomarkers in the diagnosis of disease have been carried out, the results have not led to a useful, definitive method. Significant overlap in values for these biomarkers between cases and controls limits their utility as diagnostic biomarkers. In addition, several reports have demonstrated the lack of correlation between amyloid plaque load and the degree of dementia, suggesting that the former may not directly relate to the latter. At present, there is a need for an improved tool more reliable than those currently available for the diagnosis of Alzheimer's disease.
- Another class of biomarkers that may have utility in the diagnosis of AD, are biomarkers that reflect neuronal death rather than specific markers of disease pathogenesis. Such markers may provide information about disease progression related to functional outcome, and have utility in future clinical trials testing therapeutic efficacy.
- An example of such a biomarker is Visinin-like protein 1 (VLP-1), a calcium sensor protein which is expressed in high abundance in neurons of the central nervous system. VLP-1 is elevated in the CSF of rats following transient focal ischemia, and is detectable in elevated concentrations in the plasma of ischemic stroke patients. The use of VLP-1 as a marker for brain damage and for AD has been described in PCT publication WO 2006/012351. Thus, while VLP-1 indicates brain damage, it has also been identified as a useful diagnostic for Alzheimer's disease. Alternative causes for brain damage are associated with readily identified conditions such as stroke, asphyxiation, invasive surgery and trauma.
- The invention provides methods that include the VLP-1 biomarker to predict the imminence and progression of Alzheimer's disease. When an elevated level of VLP-1 is detected in bodily fluids, e.g., in cerebrospinal fluid or in serum, it is associated with brain injury such as that caused by Alzheimer's disease (AD).
- Thus, the invention is directed to a method to diagnose AD which method comprises evaluating VLP-1 in combination with at least one other biomarker selected from amyloid-β peptide (Aβ), hyperphosphorylated Tau (pTau) and total Tau (tTau). Evaluating VLP-1 in combination with another biomarker gives rise to an improved diagnostic method better than that of relying on the interpretation of any one biomarker alone. Evaluating VLP-1 in combination with copy presence of a ApoE ε4 allele also improves the diagnostic method.
- Also included within the scope of the invention are kits for diagnosis which contain reagents for quantifying the biomarker targets including VLP-1 and at least one of Aβ, pTau, tTau present in the biological fluid samples, as well as kits that contain reagents for quantifying VLP-1 and assessing the presence or absence of the ApoE2 4 allele.
-
FIG. 1 shows CSF VLP-1 levels in AD patients and controls. The line within the box represents the median value; the box encompasses 25th-75th percentiles; and the error bars encompass the 10th-90th percentiles. A significant difference was found in control vs. AD patients; p<0.001, Student's T-test. -
FIGS. 2A and 2B show the predictive ability of AD biomarkers to diagnose AD vs. Control.FIG. 2A shows the area under ROC curve (AuC) and its 95% confidence interval for VLP-1, Aβ, pTau and an optimum linear combination of all 3 biomarkers (ALL).FIG. 2B shows CSF levels of VLP-1, Aβ, and pTau plotted on a 3-D graph (controls, solid circles; AD, open circles). -
FIG. 3 shows VLP-1 levels by ApoE genotype. Mean CSF VLP-1 levels are graphed according to ApoE genotypes (ε3/ε3, ε3/ε4,). Mean VLP-1 levels in ApoE ε4/ε4 were more than twice that in ε3/ε3 individuals; *p<0.0 (3/3 vs. 4/4); **p<0.0 (3/4 vs. 4/4); using ANOVA with post-hoc Tukey's test. -
FIGS. 4A-4C show correlation of VLP-1 and pTau levels in CSF.FIG. 4A shows CSF VLP-1 levels plotted against Aβ.FIG. 4B shows CSF VLP-1 levels plotted against tTau.FIG. 4C shows CSF VLP-1 levels plotted against pTau. Correlation was most striking between VLP-1 and pTau (r2=0.73) compared to the others. - As described in the above-cited PCT publication WO 2006/012351, VLP-1 levels in biological fluids, especially cerebrospinal fluid correlate with the incidence of brain damage associated with Alzheimer's disease. It has now been found that by combining the results of determining VLP-1 levels with at least one alternative marker, selected from amyloid β peptide, hyperphosphorylated Tau, and total Tau, the accuracy of diagnosis can be improved. The accuracy can also be improved by correlation of VLP-1 levels with an ApoE ε4 genotype.
- Methods for evaluating the levels of each of these markers are known in the art. Literature references which describe such methods are set forth in the examples below. However, the method of the invention is not limited to employing these precise methods; any method for determining these markers or for assessing the presence of an ApoE 4 allele may be used. Such methods include immunoassays, chromatographic assays and the like.
- The levels in a patient to be diagnosed are determined and compared with levels in normal controls. Typically, a standard value for normals with appropriate error bars can be generated by averaging the results from a statistically meaningful sample of individuals known not to be afflicted by this condition. As noted herein, typically, in CSF, levels of VLP-1, tTau and pTau are significantly higher in AD patients and levels of Aβ1-42 are lower. As noted in the examples below, the average values for controls with appropriate error bars are shown in Table 2.
- The levels of the relevant markers in normal controls may be determined experimentally in the course of performing the method of the invention with respect to a test subject on a statistically meaningful number of subjects, typically 10 or more subjects, 20 or more subjects, 30 or more subjects or 50 or more subjects. However, values associated with levels of these markers in normal controls may also be published in the literature; in such instances it is unnecessary to determine the levels of a published marker in normal controls, but rather these values can be obtained by consulting the literature. The practitioner will understand when, and whether, published values for the level of a particular marker is sufficiently reliable, and has been determined by methods sufficiently similar to that used in performing the test on test subjects to be satisfactory for making the comparison.
- The kits designed for conducting the method of the invention will contain reagents for the determination of VLP-1 plus the reagents for determination of at least one additional marker or for determining the presence of an ApoE 4 allele. The nature of the reagents will depend on the type of methodology used in performing the test. If immunological assays such as radioimmunoassays, ELISA's, or Western blot are to be employed, antibodies reactive with the marker, such as VLP-1, will be included. Such antibodies may be polyclonal or monoclonal or recombinantly produced. As the assays are performed in vitro, humanized forms are unnecessary, but are not excluded from use in the practice of the invention. Generally, these are less preferred in this context, however, as the affinity tends to be lower.
- Typically, also, the kits will contain instructions for conducting the determinations of marker levels, and may further contain directions for statistical comparisons between levels in test subjects and those in normal controls.
- The test subjects are typically those persons identified as at risk for Alzheimer's disease but may also include individuals who are lacking in any symptoms that would lead to a suspicion of susceptibility. The subjects may have already been shown to have elevated levels of one of the markers employed in the method of the invention, in which case the result of the previous test in combination with the test for at least one additional marker constitute the data provided for conduct of the method of the invention. Thus, the invention further includes a method of simply assessing the results of previous determinations of one or more markers in combination with an level of VLP-1 and need not include physically determining the levels of these previously measured markers. The methods of the invention also include simply comparing the levels of VLP-1 and at least one additional marker selected from amyloid-β peptide, hyperphosphorylated Tau, and total Tau that have previously been determined in a test subject with levels previously determined in control subjects and determining whether the levels of both markers are different in the test subject in the predicted way in order to determine the presence of absence of Alzheimer's disease in the test subject.
- Biological fluids that are possible sample sources include blood and fractions thereof, such as plasma or serum, cerebrospinal fluid, urine, and lymphatic fluids. Serum or plasma or urine are more convenient. Cerebrospinal fluid is the preferred source for sampling.
- The following examples are intended to illustrate but not to limit the invention.
- Thirty-three (33) patients with a clinical diagnosis of AD (NINCDS-ADRDA criteria for probable AD) were evaluated. Twenty-four (24) healthy controls also participated and were free of neurological or psychiatric disorders. All subjects underwent a clinical evaluation which included a medical history, physical and neuropsychiatric evaluation, and a Mini-Mental State Examination (MMSE). ApoE genotype was also assessed. See Table 1.
-
TABLE 1 Demographics of Study Subjects N Age Female Duration apoE4 MMSE Controls 24 68.5 ± 1.3 11 (46%) N/A ND 29.8 ± 0.1 AD 33 64.9 ± 2.5 18 (55%) 3.9 ± 0.4 25 23.0 ± 1.1 p value 0.248 <0.001 - The mean age of subjects in each group did not differ significantly (controls: 68.5 years vs. AD 64.9 years). Gender distribution was also not significantly different (46% vs. 55%). The mean duration of disease in the AD group was 3.9 years. MMSE scores were assessed and were significantly lower in the AD group (23.0 vs. 29.8, p<0.001).
- CSF samples were collected by lumbar puncture at the L3/L4 interspace. The first portion of the sample was discarded, and the subsequent 10 mls was collected in polypropylene tubes, centrifuged at 2,000 g for 10 min (to eliminate cells), and frozen in aliquots at −80° C. All samples had less than 500 erythrocytes/μl.
- CSF samples were assayed for total Tau (tTau) and hyperphosphorylated Tau (pTau at Thr-181), and Aβ1-42 using sandwich ELISA's, as previously described (Blennow, K., et al., Mol. Chem. Neuropathol. (1995) 26:231-245; Vanmechelen, E., et al., Neurosci. Lett. (2000) 285:49-52). CSF VLP-1 was measured using a sandwich ELISA (monoclonal antibody for capture and rabbit polyclonal antibody for detection), as described (Laterza, O. F., et al., Clin. Chem. (2006) 52:1713-1721).
- The CSF tTau and pTau levels were significantly higher in AD patients compared to controls (p<0.001 for both, Table 2) consistent with earlier findings (Arai, H., et al., Ann. Neurol. (1995) 38:649-652; Blennow, et al., supra; Tapiola, T., et al., Neuroreport (1997) 8:3961-3963; Andreasen, N., et al., World J. Biol. Psychiatry (2003) 4:147-155). Aβ1-42 levels were lower in AD patients compared to controls (p<0.001, Table 2), consistent with numerous other studies (Arai, et al., supra; Blennow, et al., supra; Tapiola, et al., supra; Andreasen, et al., supra). The units in Table 2 are pg/mL of CSF.
-
TABLE 2 CSF Levels in Controls and AD Patients tTau pTau Aβ1-42 VLP-1 Controls 395 ± 42 61 ± 6 698 ± 47 234 ± 21 AD 735 ± 77 100 ± 7 471 ± 30 387 ± 27 p value <0.001 <0.001 <0.001 <0.001 - VLP-1 levels in the CSF were significantly higher in the AD patients compared to controls (387±27 vs. 234±21, p<0.001,
FIG. 1 ). - Differences in patient characteristics and biomarkers between two groups were compared using chi-square test or student's t-test as appropriate. ANOVA with a post-hoc Tukey's test was used for comparisons between multiple groups. The diagnostic ability of these biomarkers was evaluated using receiver operating characteristic (ROC) curves which plot true positive rates (sensitivity) versus the false positive rates (1-specificity) across all possible thresholds. As a global measure for the accuracy of diagnosis, the area under ROC curve (AUC) was also calculated for each individual biomarker as well as for an optimum linear combination of all biomarkers (Xiong, C., et al., Med. Decis. Making (2004) 24:659-669). All the statistical comparisons were implemented using the statistical package SAS (version 9) while all ROC analyses were performed with ROCKIT, a widely used freeware available from the Kurt Rossmann Laboratories at the University of Chicago. A p value under 0.05 was taken to indicate significance and all statistical tests were two-sided.
- We performed a receiver operating characteristic (ROC) analysis for each individual biomarker alone compared to the combination of all biomarkers. The area under the ROC curves for VLP-1, Aβ, pTau, and an optimum linear combination of all biomarkers is shown in
FIG. 2A . The linear combination resulted in an approximately 5% improvement in diagnostic accuracy. The 3-D plot (FIG. 2B ) demonstrates that higher levels of VLP-1 and pTau, and lower levels of Aβ1-42 result in AD diagnosis. - Mean CSF VLP-1 levels were correlated by different ApoE genotypes within the cohort of AD patients. ApoE ε4/ε4 individuals (n=5) had the highest levels of VLP-1, followed by ε3/ε4 (n=20) and ε3/ε3 (n=8) individuals (
FIG. 3 ). The ApoE ε4 genotype may be associated with increased neuronal death. - Correlations between VLP-1 and tTau, pTau, or Aβ1-42 were performed; VLP-1 and shown in
FIGS. 4A-4C . pTau showed the greatest correlation (FIG. 4C , r2=0.73).
Claims (11)
1. A kit for diagnosing Alzheimer's disease in a subject, which comprises antibodies immunoreactive with VLP-1 and antibodies immunoreactive with at least one of Aβ1-42, p-tau and t-tau, along with reagents for detecting said immunoreaction.
2. The kit of claim 1 which comprises antibodies immunoreactive with VLP-1 and antibodies reactive Aβ1-42.
3. The kit of claim 1 which further contains antibodies immunoreactive with p-tau or with t-tau.
4. The kit of claim 3 which contains antibodies immunoreactive with p-tau and immunoreactive with t-tau.
5. The kit of claim 1 wherein the antibodies are monoclonal.
6. The kit of claim 1 which compriese reagents for ELISA or radio immunoassays.
7. A method of diagnosing Alzheimer's disease in a subject which method comprises determining the level of VLP-1 in a sample of biological fluid of a human subject in combination with determining the presence or absence of an ApoE ε4 allele in said subject;
comparing the level of said VLP-1 with the level of VLP-1 in normal controls;
wherein a higher level of VLP-1 in combination with the presence of an ApoE ε4 allele in said subject results in a diagnosis for said subject of Alzheimer's disease.
8. The method of claim 7 wherein the sample is obtained from cerebrospinal fluid.
9. The method of claim 7 wherein the sample is obtained from plasma or serum.
10. A kit for diagnosing Alzheimer's disease in a subject which comprises reagents for conducting the method of claim 7 .
11. The kit of claim 10 , which comprises antibodies immunoreactive with VLP-1 and reagents for determining the presence of an ApoE ε4 allele.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/929,600 US20130288280A1 (en) | 2007-08-21 | 2013-06-27 | Alzheimer's diagnosis |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95713207P | 2007-08-21 | 2007-08-21 | |
PCT/US2008/073851 WO2009026432A1 (en) | 2007-08-21 | 2008-08-21 | Improved alzheimer's diagnosis |
US67415311A | 2011-02-24 | 2011-02-24 | |
US13/929,600 US20130288280A1 (en) | 2007-08-21 | 2013-06-27 | Alzheimer's diagnosis |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/073851 Division WO2009026432A1 (en) | 2007-08-21 | 2008-08-21 | Improved alzheimer's diagnosis |
US67415311A Division | 2007-08-21 | 2011-02-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130288280A1 true US20130288280A1 (en) | 2013-10-31 |
Family
ID=40378643
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/674,153 Active 2029-01-22 US8481277B2 (en) | 2007-08-21 | 2008-08-21 | Alzheimer's diagnosis |
US13/929,600 Abandoned US20130288280A1 (en) | 2007-08-21 | 2013-06-27 | Alzheimer's diagnosis |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/674,153 Active 2029-01-22 US8481277B2 (en) | 2007-08-21 | 2008-08-21 | Alzheimer's diagnosis |
Country Status (5)
Country | Link |
---|---|
US (2) | US8481277B2 (en) |
EP (1) | EP2198292A4 (en) |
JP (1) | JP2010537200A (en) |
CA (1) | CA2697045C (en) |
WO (1) | WO2009026432A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8926974B2 (en) | 2012-08-16 | 2015-01-06 | Ipierian, Inc. | Methods of treating a tauopathy |
US8980271B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
US10400018B2 (en) | 2014-02-14 | 2019-09-03 | Ipierian, Inc. | Tau peptides, anti-tau antibodies, and methods of use thereof |
WO2021260193A1 (en) * | 2020-06-25 | 2021-12-30 | Medimmune Limited | Prevention of axonal damage using antibody binding to amyloid beta 1-42 |
WO2022187678A1 (en) * | 2021-03-04 | 2022-09-09 | Duke University | Compositions and methods for the diagnosis and treatment of alzheimer's disease or other neurodegenerative disorders |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100136584A1 (en) * | 2008-09-22 | 2010-06-03 | Icb International, Inc. | Methods for using antibodies and analogs thereof |
GB0912394D0 (en) * | 2009-07-16 | 2009-08-26 | Univ Birmingham | Screening methods |
ES2675993T3 (en) * | 2011-10-14 | 2018-07-16 | Centre National De La Recherche Scientifique | Diagnostic procedure, prognosis or treatment of neurodegenerative diseases |
TWM474138U (en) * | 2013-06-18 | 2014-03-11 | 磁量生技股份有限公司 | A system for diagnosing alzeheimer's disease |
CN109477149A (en) | 2016-07-20 | 2019-03-15 | 生物技术Rna制药有限公司 | Select new epitope as the disease specific target for treatment with enhancing effect |
JP6359158B2 (en) * | 2017-07-25 | 2018-07-18 | 株式会社Mcbi | Biomarker for cognitive dysfunction disease and method for detecting cognitive dysfunction disease using the biomarker |
CN112703402A (en) * | 2018-07-19 | 2021-04-23 | 吉宁特有限公司 | Methods of identifying individuals as having or at risk of developing amyloid-positive dementia based on marker molecules and related uses |
CN114242175A (en) * | 2021-12-22 | 2022-03-25 | 香港中文大学深圳研究院 | Method and system for evaluating brain white matter high signal volume |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5837672A (en) * | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
AU2001273675A1 (en) * | 2000-07-03 | 2002-01-14 | University Of South Florida | Methods and assays for diagnosing alzheimer's disease |
AU2003253883A1 (en) * | 2002-07-15 | 2004-02-02 | The Johns Hopkins University | Neuronal and optic nerve gene expression patterns |
EP1694816B1 (en) * | 2003-11-07 | 2013-08-28 | Ciphergen Biosystems, Inc. | Biomarkers for alzheimer's disease |
EP2514837B1 (en) | 2004-06-25 | 2016-02-10 | Washington University | Markers for brain damage |
US7255433B2 (en) * | 2004-06-28 | 2007-08-14 | Nu-Kote International, Inc. | Multiple pass aqueous MICR inkjet ink printing |
-
2008
- 2008-08-21 US US12/674,153 patent/US8481277B2/en active Active
- 2008-08-21 WO PCT/US2008/073851 patent/WO2009026432A1/en active Application Filing
- 2008-08-21 CA CA2697045A patent/CA2697045C/en active Active
- 2008-08-21 JP JP2010522022A patent/JP2010537200A/en not_active Withdrawn
- 2008-08-21 EP EP08827578A patent/EP2198292A4/en not_active Ceased
-
2013
- 2013-06-27 US US13/929,600 patent/US20130288280A1/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
O'Bryant et al., 2010, Arch Neurol, 67(9):1077-81 * |
O'Bryant et al., 2011, Dement Geriatr Cogn Disord, 32:55-62 * |
Ravetti et al., 2008, PLoS One, 3(9),e3111: 1-12 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8926974B2 (en) | 2012-08-16 | 2015-01-06 | Ipierian, Inc. | Methods of treating a tauopathy |
US9567395B2 (en) | 2012-08-16 | 2017-02-14 | Ipierian, Inc. | Methods of treating a tauopathy |
US10040847B2 (en) | 2012-08-16 | 2018-08-07 | Ipierian, Inc. | Methods of treating a tauopathy |
US8980271B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
US9051367B2 (en) | 2013-01-18 | 2015-06-09 | Ipierian, Inc. | Methods of treating a tauopathy |
US9447180B2 (en) | 2013-01-18 | 2016-09-20 | Ipierian, Inc. | Methods of treating a tauopathy |
US9777058B2 (en) | 2013-01-18 | 2017-10-03 | Ipierian, Inc. | Methods of treating a tauopathy |
US10400018B2 (en) | 2014-02-14 | 2019-09-03 | Ipierian, Inc. | Tau peptides, anti-tau antibodies, and methods of use thereof |
WO2021260193A1 (en) * | 2020-06-25 | 2021-12-30 | Medimmune Limited | Prevention of axonal damage using antibody binding to amyloid beta 1-42 |
WO2022187678A1 (en) * | 2021-03-04 | 2022-09-09 | Duke University | Compositions and methods for the diagnosis and treatment of alzheimer's disease or other neurodegenerative disorders |
Also Published As
Publication number | Publication date |
---|---|
US20110136254A1 (en) | 2011-06-09 |
CA2697045C (en) | 2019-12-31 |
EP2198292A4 (en) | 2010-09-08 |
CA2697045A1 (en) | 2009-02-26 |
EP2198292A1 (en) | 2010-06-23 |
JP2010537200A (en) | 2010-12-02 |
WO2009026432A1 (en) | 2009-02-26 |
US8481277B2 (en) | 2013-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8481277B2 (en) | Alzheimer's diagnosis | |
EP3540442B1 (en) | Surrogate biomarker for evaluating intracerebral amyloid beta peptide accumulation and method for analysis thereof | |
US20240003913A1 (en) | Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers | |
Marksteiner et al. | Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: A pilot-study | |
JP2017504808A (en) | Biomarkers and methods for early diagnosis of Alzheimer's disease | |
US20220291242A1 (en) | Method for assisting with diagnosis of alzheimer's disease or mild cognitive impairment, biomarker, reagent kit, and device | |
US20120071337A1 (en) | Methods | |
Feinkohl et al. | Plasma Amyloid concentration in alzheimer’s disease: Performance of a high-throughput amyloid assay in distinguishing alzheimer’s disease cases from controls | |
KR20180083909A (en) | For the diagnosis or prediction of Alzheimer &apos; s disease, or for the diagnosis of Parkinson &apos; | |
Perez-Grijalba et al. | Aβ 1-17 is a major amyloid-β fragment isoform in cerebrospinal fluid and blood with possible diagnostic value in Alzheimer's disease | |
EP3452830B1 (en) | Assay for the diagnosis of a neurological disease | |
WO2021009074A1 (en) | Novel markers as early predictors of alzheimer's pathology | |
US11543418B2 (en) | Biomarker for cognitive dysfunction disease and method for detecting cognitive dysfunction disease using biomarker | |
KR102254053B1 (en) | Biomarker for detecting amyloid beta accumulation in brain of subject with normal cognitive function or mild cognitive impairment using blood sample | |
EP4067905A1 (en) | Method for assisting diagnosis of parkinson's disease, biomarker, reagent kit, and device | |
JP2005539228A (en) | Diagnostic methods specific to Alzheimer's patients with mild cognitive impairment | |
Schoonenboom et al. | Copyright© 2005 by The American Association for Clinical Chemistry |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: WASHINGTON UNIVERSITY, MISSOURI Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LADENSON, JACK H.;LATERZA, OMAR;MODUR, VIJAY;SIGNING DATES FROM 20101217 TO 20110131;REEL/FRAME:031052/0034 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |